Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
HHS | NIH | National Cancer Institute (P30 CA008748)
HHS | NIH | National Cancer Institute (R35 CA283988)
Hunter Douglas Fellowship in Breast Cancer Research (13459)
BRIA Postdoctoral Researcher Innovation Grant (18057)
- License Information
-
More Information
Article History
Received: 24 September 2024
Revised: 6 December 2024
Accepted: 10 December 2024
First Online: 7 February 2025
Disclosure and competing interests statement
: Craig B Thompson is a founder of Agios Pharmaceuticals. He also serves on the Board of Directors of Regeneron and Charles River Laboratories. The other authors declare no competing interests.
